Press Releases August 6, 2026 07:00 AM

American Shared Hospital Services Announces Second Quarter 2026 Financial Results Conference Call

American Shared Hospital Services schedules Q2 2026 earnings call amidst expansion plans in advanced cancer treatment services

By Sofia Navarro
Share
Twitter Reddit Facebook LinkedIn
AMS

American Shared Hospital Services announced its upcoming Q2 2026 financial results conference call, highlighting continued growth and expansion in stereotactic radiosurgery, Gamma Knife, proton therapy, and advanced radiation cancer treatments. The company collaborates with health systems to share in capital investment and profitability while focusing on local cancer care accessibility.

American Shared Hospital Services Announces Second Quarter 2026 Financial Results Conference Call
AMS
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • AMERICAN Shared Hospital Services provides advanced cancer treatment equipment leasing and direct patient care services, including Gamma Knife and proton therapy.
  • The company plans to expand its cancer treatment services across North and South America, working in partnership with health systems.
  • Financial results will be released August 13, 2026, with a conference call scheduled to discuss the quarter's performance.
  • The healthcare and medical equipment leasing sectors are impacted, particularly oncology treatment and healthcare services markets.

SAN FRANCISCO, Aug. 06, 2026 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the "Company"), a leading provider of stereotactic radiosurgery equipment and advanced radiation therapy cancer treatment services through its equipment leasing and direct patient care services segments, today announced that the Company will hold a conference call to discuss its second quarter 2026 financial results on August 13th at 1:00 pm ET.

The second quarter 2026 financial results press release will be issued before the market opens on August 13th, 2026.

Teleconference and Webcast Information

To participate, domestic callers may dial 1-844-413-3972 and international callers may dial 1-412-317-5776 at least 10 minutes prior to the start of the call and ask to join the American Shared Hospital Services call.

A simultaneous webcast of the call may be accessed through the Company's website, www.ashs.com or directly:

https://event.choruscall.com/mediaframe/webcast.html?webcastid=v8y3MbI1

A replay of the call will be available at 1-855-669-9658 or 1-412-317-0088, access code 2844456, through August 20, 2026. The call will also be available for replay on the Company’s website at www.ashs.com.

About American Shared Hospital Services (NYSE American: AMS)

American Shared Hospital Services (AMS) is a leading provider of turnkey solutions to cancer treatment centers, health systems, and cancer networks in North and South America. The company works closely with its partners to develop and grow their cancer service lines and provide integrated cancer care to patients in a convenient local setting close to home. For centers under health system partnerships, the Company and its health system partners share in the capital investment cost and profitability of the operations based on their respective ownership interests. For more information, please visit: www.ashs.com

Safe Harbor Statement

This press release may be deemed to contain certain forward-looking statements with respect to the financial condition, results of operations and future plans of American Shared Hospital Services including statements regarding the expected continued growth of the Company and the expansion of the Company’s Gamma Knife, proton therapy and advanced radiation therapy cancer treatment services businesses, which involve risks and uncertainties including, but not limited to, the risks of economic and market conditions, the risk of compliance with debt covenants, the risks of variability of financial results between quarters, the risks of the Gamma Knife, proton therapy and advanced radiation therapy cancer treatment services businesses, the risks of changes to CMS reimbursement rates or reimbursement methodology, the risks of the timing, financing, and operations of the Company’s Gamma Knife, proton therapy, and advanced radiation therapy cancer treatment services businesses, the risk of expanding within or into new markets, the risk that the integration or continued operation of acquired businesses could adversely affect financial results and the risk that current and future acquisitions may negatively affect the Company’s financial position. Further information on potential factors that could affect the financial condition, results of operations and future plans of American Shared Hospital Services is included in the filings of the Company with the Securities and Exchange Commission, including the Company's first quarter report on Form 10-Q for the quarter ended March 31, 2026 and the Annual Report on Form 10-K for the year ended December 31, 2025.

Contacts:
American Shared Hospital Services
Ray Stachowiak, Executive Chairman
[email protected]

Investor Relations
Kirin Smith, President
PCG Advisory, Inc.
[email protected]


Risks

  • Economic and market conditions may adversely affect financial performance.
  • Risks related to compliance with debt covenants and variability in quarterly results.
  • Potential impact of changes in CMS reimbursement rates or methodologies on profitability and operations.

More from Press Releases

Safe Harbor's Cannabis-Focused 401(k) Plan Gains Early Adoption as Canopy HR Names It the Recommended Retirement Solution for its Clients Aug 6, 2026 Corbus Pharmaceuticals Reports Q2 2026 Financial Results and Provides a Corporate Update Aug 6, 2026 ALX Oncology Reports Second Quarter 2026 Financial Results and Provides Corporate Update Aug 6, 2026 Theriva™ Biologics Announces First Patient Dosed in VIRAGE2 Phase 2a Clinical Trial to Evaluate More Frequent Dosing of VCN-01 (zabilugene almadenorepvec) in First-Line Patients with Metastatic Pancreatic Ductal Adenocarcinoma Aug 6, 2026 Ascendis Announces COACH Week 78 Results and Provides Update on Achondroplasia Programs and YUVIWEL® Uptake in the U.S. Aug 6, 2026